- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 25
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 25, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 25.
Number 5: With the Graham-Cassidy bill dead in the Senate, efforts at healthcare reform have turned to the issue of the high cost of prescription drugs.
Number 4: The European Medicines Agency has warned that it could lose 94% of its staff when it is forced to relocate from its current home in London as the United Kingdom finalizes its withdrawal from the European Union.
Number 3: Celltrion and Teva’s rituximab biosimilar CT-P10, currently under review by the FDA, shows comparable safety and efficacy to its reference, Rituxan, in a new network meta-analysis.
Number 2: Amgen has filed a new Biologics Price Competition and Innovation Act lawsuit against rival drug maker, Mylan. Amgen asserts that Mylan infringed on 2 patents covering Neulasta when it developed its pegfilgrastim biosimilar.
Number 1: AbbVie, maker of Humira, has reached a settlement with Amgen concerning its adalimumab biosimilar, Amgevita. The agreement clears the way for the biosimilar to launch in the European Union in 2018, and in the United States in 2023.
Finally, last week, our newsletter for your input on what factors will determine clinical uptake of the newly approved bevacizumab biosimilar. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
